As of January 21, 2010, Genomic Health now offers the Oncotype DX colon cancer test, the first commercially-available multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
"We are pleased to deliver a new model for assessing recurrence risk in patients diagnosed with stage II colon cancer that is based on rigorous scientific research conducted with our clinical collaborators at the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Cleveland Clinic and the QUASAR study group," said Steven Shak, M.D., chief medical officer, Genomic Health. "We believe the availability of the Oncotype DX colon cancer test will allow physicians, for the first time, to go beyond the limited set of clinical and pathologic markers they currently use in order to make a more precise risk assessment in the treatment planning for stage II colon cancer patients."
For its colon cancer program, Genomic Health and its collaborators used the same rigorous clinical development strategy and standardized quantitative technology designed for the company's Oncotype DX breast cancer test. The NSABP conducted three development studies and Cleveland Clinic conducted one development study, all of which were funded by Genomic Health, analyzing 761 genes from 1,851 patients with stage II and III colon cancer. The final set of seven recurrence and five reference genes were then independently evaluated in 1,436 stage II colon cancer patients in the QUASAR validation study.
For a quick overview of the colon test, read our article highlighting some of the frequently asked questions about it. In addition, Genomic Health will be hosting a webinar for the advocate community to discuss the new colon cancer test and answer any questions. Below are details on the webinar and information on how to RSVP.
- Wednesday, February 17 at 1:00 pm PT / 4:00 pm ET
- Thursday, February 18 at 9:00 am PT / 12 noon ET
Please note that two dates are offered to accommodate scheduling conflicts, but the content will be the same for both calls. If you are interested in participating, please send an email with your name, email address, and advocate affiliation to Jessica Denning, Corporate Communications Coordinator, at jdenning@genomichealth.com.
*Availability in New York is pending review by the state, as is required for all laboratory developed tests.